Monday, 24 Feb 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
04 Feb 2017 Social Sarilumab (anti-IL-6) "Kevzara" approved by Health Canada for the Rx of RA. Dose 200 mg sc EOW. Let IL6 Wars begin! https://t.co/v3FnfHGUgh
07 Sep 2016 Social EU grants approval for Orencia (abatacept; IV or SC) for MTX naive (early) RA patients with moderate-severe disease https://t.co/gcGbESdxCp
10 Oct 2018 Social Study from 2018 International Congress on Spondyloarthritides shows that women with ankylosing spondylitis are less responsive to biologics, were less adherent and had worse Pain, ASDAS scores vs men. Study of 359 AS pts over 5 yrs https://t.co/dVIfGM4eTF
24 Jun 2019 Social "Therapeutic Update: Biosimilars in Rheumatology" video series features nine experts talking about biosimilars, sponsored by Sandoz, Inc. Visit RheumNow to watch: https://t.co/1vmnEJqOSi #sponsored #biosimilars
31 May 2015 Social Autoinjector market expected to grow to $2.5 billion by 2020. http://t.co/QXtaMziYXZ
28 Aug 2017 Social RT @DanielHSolomon: Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease — NEJM how will this affect rheumatology? https:/…
07 Feb 2016 Social Latex Allergies apply to some, biologics; but Cimzia, Actemra, Orencia, Kineret, Enbrel powder vials are safe https://t.co/DtqkwM9edD
13 Oct 2016 Social Global biosimilars sales = 3.5 billion in 2015; poised to reach $15.6 billion by 2022. https://t.co/TATv2rgYTM
14 Aug 2019 Social Lilly announces the results of its phase 4 trial comparing Taltz (IL-17) to Tremfya (IL-23) in mod-severe plaque psoriasis. Taltz had superior skin clearance (PASI 100) at week 12, better PASI 75 at week 2 and PASI 90 at weeks 4 and 8. https://t.co/GzfZoepUrK
13 Apr 2017 Social Is BIOSIMILAR Safety, Switching or Cost an issue for patients? Patients please vote 5 quick questions for patients https://t.co/660sMwL1V4
09 Apr 2018 Social 2015 US Pharma donated $116 million to Pt advocacy groups. For example Patients for Biologics Safety & Access (who opposes biosimilar substitution and includes Crohn’s & Colitis, Arthritis & Lupus Foundations) accepted $9.1 million from drug companies https://t.co/i3WDjNHu6f
13 Nov 2019 Social RT @CCalabreseDO: Continue or stop biologics for RA if pregnant? Abstr# 2292 and 2279 show increase in flares, GC use, if biologics stopped…
14 Apr 2017 Social Biosimilars are suppose to save alot of money, but for whom? Patients can vote on this question and more @ RheumNow https://t.co/VWkfaC6RuN
04 Nov 2017 Social RT @_connectedcare: Reminder slide re Biologics & which diseases they work in #ACR17 https://t.co/4ClkyiqdkO
02 Jan 2017 Social Hospira (biosimilar division of Pfizer) began to ship Inflectra biosimilar to U.S. wholesalers on Nov. 21 & has a sales force in place
12 Nov 2019 Social RT @hausmannMD: Telitacicept is a recombinant fusion protein with the extracellular domain of TACI and the FC domain of human IgG1. #ACR19…
12 May 2017 Social Uptacitinib (Abbvie Jak 1 inhibitor) shows efficacy in Crohns dz (CELESTE RCTl) w/ remission rates at 6 &24 mg bid https://t.co/ssZT2D6nWk
07 Nov 2017 Social RT @Janetbirdope: #GAMECHANGER. If not responding to tociluzimab in RA you can respond to switch to 200 mg sarilab #acr17 @rheumnow #2468 h…
08 Jun 2016 Social Tofacitinib (Xeljanz) presentations at EULAR reviewed in this press release. https://t.co/EjcGrddmOA
15 Feb 2020 Social RT @Janetbirdope: Do we need another IL6 inhibitor for rheumatic diseases. Tocilizumab is off patent in USA and Europe. We have Sarilumab b…